Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatmentCiro Celsa, Johann von Felden, Marco Enea et al.|Hepatology|2024Cited by 52
Platelet Functional Profile Is Altered in Metabolic Dysfunction‐Associated Steatotic Liver DiseaseMarco Castelli, Andrea Dalbeni|Liver International|2025Cited by 6